Latest news with #Albemarle
Yahoo
4 days ago
- Business
- Yahoo
Albemarle (ALB) Rises As Market Takes a Dip: Key Facts
Albemarle (ALB) ended the recent trading session at $77.07, demonstrating a +1.76% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.01%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.05%. Shares of the specialty chemicals company have appreciated by 27.51% over the course of the past month, outperforming the Basic Materials sector's gain of 1.67%, and the S&P 500's gain of 5.37%. The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is scheduled to release its earnings on July 30, 2025. On that day, Albemarle is projected to report earnings of -$0.83 per share, which would represent a year-over-year decline of 2175%. Meanwhile, our latest consensus estimate is calling for revenue of $1.23 billion, down 13.67% from the prior-year quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$2.02 per share and revenue of $4.86 billion. These totals would mark changes of +13.68% and -9.54%, respectively, from last year. Any recent changes to analyst estimates for Albemarle should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 24.78% lower. Albemarle is currently a Zacks Rank #4 (Sell). The Chemical - Diversified industry is part of the Basic Materials sector. This industry, currently bearing a Zacks Industry Rank of 228, finds itself in the bottom 8% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
5 days ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: Pepsi Stock Turns Higher; Elevance Health Tumbles
Key Takeaways The S&P 500 added 0.5% on Thursday, July 17, 2025, notching a record closing high for the first time in a week as June retail sales exceeded economists' forecasts. Pepsi stock popped higher as the soda and snack giant topped quarterly estimates and lifted its profit outlook. Elevance Health slashed its full-year guidance, citing ACA and Medicaid cost pressure, and shares of the insurer U.S. equities indexes pushed higher Thursday as a report revealed an increase in retail sales in June, suggesting that consumer spending remains strong despite tariff concerns. The S&P 500 advanced 0.5% to reach a record closing high, surpassing the all-time mark set by the benchmark index a week ago. The Dow also added 0.5%, while the Nasdaq jumped 0.7%, extending its string of consecutive record-setting daily closes to four. Read Investopedia's full coverage of today's trading here. Snap-On (SNA) shares rose 7.9%, scoring Thursday's top performance in the S&P 500, after the provider of professional tools topped second-quarter sales and profit estimates. The company highlighted the resilience of its gross margins despite trade-related uncertainties, a return to sales growth in its U.S. tools segment, and strong sales from its vehicle diagnostic and repair information products. Lithium prices gained ground after China's Zangge Mining said it stopped lithium production in Qinghai province following directives from local officials. Shares of Albemarle (ALB), the world's largest lithium miner, surged 7.6%. Albemarle and other producers have cut employees and reduced expansion plans as they navigate a prolonged slump in the price of the key battery component. PepsiCo (PEP) reported better-than-expected sales and profits for the second quarter, and shares of the soft-drink and snack-food giant jumped 7.5%. The parent company of brands like Mountain Dew and Lay's potato chips offered a slightly improved forecast for core profits in 2025, noting that the weaker U.S. dollar contributed to its earnings outlook. Elevance Health (ELV) shares plunged 12.2%, losing the most of any S&P 500 stock on Thursday. The parent of the Wellpoint, Anthem, and Carelon healthcare services fell short of quarterly profit estimates and lowered its full-year forecast, citing higher costs for Affordable Care Act and Medicaid coverage. Other health insurance stocks also moved lower. Molina Healthcare (MOH) shares slipped 5.5%, while shares of Centene (CNC), which pulled its full-year guidance earlier this month amid cost pressures, sank 4.2%. Abbott Laboratories (ABT) posted better-than-expected quarterly revenue and adjusted profit but narrowed its full-year outlook. The drugmaker reported a year-over-year sales decline in its diagnostics segment, pressured by drop in demand for COVID-19 tests, although sales in its nutrition and established pharmaceuticals businesses were higher than a year ago. Abbott shares fell 8.5%. Second-quarter profits from advertising and media firm Omnicom (OMC) were down year-over-year, reflecting elevated costs related to the ongoing acquisition of competitor Interpublic Group (IPG). Shares of both Omnicom and Interpublic Group closed Thursday's session more than 4% lower. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Lithium Miner Albemarle's Stock Pops as Chinese Miner Halts Operations
Key Takeaways Albemarle shares surged to lead S&P 500 gainers Thursday. The stock and global lithium prices were lifted by reports that a large lithium miner in China halted operations, easing concerns about an oversupply. RBC analysts recently raised their price target for Albemarle's stock, while noting that low lithium prices have remained a weakness for the (ALB) shares surged Thursday as lithium prices rose amid reports that a large lithium miner in China halted operations, easing concerns about an oversupply. Shares of Albemarle, the world's largest lithium miner, were up nearly 9% in recent trading, leading gains in the S&P 500. Sociedad Quimica y Minera, or SQM (SQM), saw its shares jump close to 8%. China's Zangge Mining Co. said government officials told the company to halt illegal mining operations and follow guidelines governing lithium resources, according to Bloomberg. The report said the company is working on preparing documents to apply to resume output. The company was not reached for comment by Investopedia in time for publication. Separately, analysts from RBC Capital Markets on Thursday lifted their price target for Albemarle stock to $80 from $76 and reiterated an "outperform" rating, while noting a key weakness from persistently low lithium prices due to oversupply. Albemarle is set to report second-quarter results after the closing bell on July 30. Albemarle's Thursday move brought the stock above $76 in recent trading, just above the $75 mean of analysts surveyed by Visible Alpha. Four of the 12 analysts give the stock a "buy" or equivalent rating, compared with seven "hold" ratings, and one "sell." Even with Thursday's gains, the shares have lost close to 12% of their value since the start of the year. This article has been updated since it was first published to include additional information and reflect more recent share price values. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-07-2025
- Business
- Yahoo
Albemarle (ALB) Dips More Than Broader Market: What You Should Know
Albemarle (ALB) closed at $70.98 in the latest trading session, marking a -4.43% move from the prior day. This change lagged the S&P 500's daily loss of 0.33%. Meanwhile, the Dow experienced a drop of 0.63%, and the technology-dominated Nasdaq saw a decrease of 0.22%. Coming into today, shares of the specialty chemicals company had gained 18.87% in the past month. In that same time, the Basic Materials sector gained 1.87%, while the S&P 500 gained 4.07%. The investment community will be paying close attention to the earnings performance of Albemarle in its upcoming release. The company is slated to reveal its earnings on July 30, 2025. On that day, Albemarle is projected to report earnings of -$0.84 per share, which would represent a year-over-year decline of 2200%. Meanwhile, our latest consensus estimate is calling for revenue of $1.23 billion, down 13.67% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.87 per share and revenue of $4.86 billion, indicating changes of +20.09% and -9.54%, respectively, compared to the previous year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Albemarle. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 17.6% lower. Albemarle presently features a Zacks Rank of #3 (Hold). The Chemical - Diversified industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 209, positioning it in the bottom 16% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
04-07-2025
- Business
- Yahoo
Albemarle (ALB) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Albemarle (ALB) closed at $67.21, marking a -1.15% move from the previous day. This change lagged the S&P 500's daily gain of 0.83%. At the same time, the Dow added 0.77%, and the tech-heavy Nasdaq gained 1.02%. The stock of specialty chemicals company has risen by 13.89% in the past month, leading the Basic Materials sector's gain of 5.33% and the S&P 500's gain of 4.99%. Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 30, 2025. The company's earnings per share (EPS) are projected to be -$0.8, reflecting a 2100% decrease from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $1.21 billion, indicating a 15.52% decline compared to the corresponding quarter of the prior year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$1.86 per share and a revenue of $4.86 billion, indicating changes of +20.51% and -9.54%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Albemarle. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 12.89% lower. Albemarle presently features a Zacks Rank of #3 (Hold). The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 215, which puts it in the bottom 13% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
